- Drug Compounding for Animals: FDA Could Improve Oversight with Better Information and Guidance [Reissued on January 8, 2016, GAO-15-671: Published: Sep 28, 2015. Publicly Released: Sep 28, 2015: ” Drugs compounded for animals offer certain medical benefits but also pose risks of causing harm or being ineffective. Specifically, drugs compounded for animals can serve as treatment options when no suitable drug approved by the Food and Drug Administration (FDA) is available. For example, no FDA-approved drugs exist to treat megacolon—a potentially lethal form of constipation—in cats, so veterinarians rely on a compounded drug for treatment. Drugs compounded for animals can also pose risks of serious harm or may be ineffective if they contain too much or too little of an active ingredient, according to scientific studies and veterinary experts. However, FDA has acknowledged that it is not practical for the agency to approve each drug compounded for every animal that requires one; as a result these drugs are not reviewed for safety and effectiveness. In addition, because states have primarily exercised responsibility for pharmacies that compound drugs for animals, the states and not FDA generally review pharmacy compounding processes.”
- Troubled Asset Relief Program: Status of Housing Programs, GAO-16-279R: Published: Jan 8, 2016. Publicly Released: Jan 8, 2016: “As of October 31, 2015, three Troubled Asset Relief Program (TARP) housing programs— Making Home Affordable (MHA), Housing Finance Agency Innovation Fund for the Hardest Hit Housing Markets (Hardest Hit Fund or HHF), and Federal Housing Administration’s Short Refinance Program (FHA Short Refinance)—remained active. Combined, the Department of the Treasury (Treasury) had obligated $37.51 billion to these three programs. As of October 31, 2015, Treasury had disbursed $18.34 billion (49 percent). The amount and percentage of disbursements varied across these programs.”
Sorry, comments are closed for this post.